Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week single-arm study of switching from premixed insulin to iGlarLixi in uncontrolled type 2 diabetes mellitus
2021-003711-25Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline to Week 24. Started Oct 2021; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-003711-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003711-25.